Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 6/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 6/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6186174 | 0.90 | PDGFRB (0.38) | GABBR2GABBR1MAPK1PDGFRBPDGFRA | |
| SCHEMBL7495679 | 0.87 | GABBR2 (0.39) | GABBR2GABBR1ADORA3ADORA2AADORA1 | |
| SCHEMBL7962438 | 0.87 | GABBR2 (0.37) | GABBR2GABBR1ADORA3ADORA2AADORA1 | |
| SCHEMBL6410703 | 0.86 | PDGFRB (0.36) | GABBR2GABBR1MAPK1PDGFRBPDGFRA | |
| SCHEMBL6863776 | 0.82 | GABBR2 (0.37) | GABBR2GABBR1KDRAURKB | |
| SCHEMBL978477 | 0.81 | KMT2A (0.36) | MAPK1MEN1KMT2A | |
| SCHEMBL4821434 | 0.80 | CNR1 (0.43) | GABBR2GABBR1MAPK1 | |
| SCHEMBL4821115 | 0.80 | GABBR2 (0.34) | GABBR2GABBR1GAA | |
| SCHEMBL4819294 | 0.77 | ALDH1A1 (0.43) | GABBR2GABBR1PDGFRBPDGFRAMEN1 | |
| SCHEMBL7830854 | 0.76 | PDE2A (0.33) | MAPK1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329663-B2 | Substituted-triazolopyrimidines as anticancer agents | WYETH (US) | 2008-02-12 | — | — | US | claimed |
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | claimed |
| US-6297251-B1 | Fungicidal trifluorophenyl-triazolopyrimidines | AMERICAN CYANAMID CO. | 2001-10-02 | — | — | US | claimed |
| EP-0975634-B1 | FUNGICIDAL TRIFLUOROPHENYL-TRIAZOLOPYRIMIDINES | BASF AG (DE) | 2001-07-04 | — | — | EP | claimed |
| US-7329663-B2 | Substituted-triazolopyrimidines as anticancer agents | WYETH (US) | 2008-02-12 | — | — | US | disclosed |
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | disclosed |
| US-6297251-B1 | Fungicidal trifluorophenyl-triazolopyrimidines | AMERICAN CYANAMID CO. | 2001-10-02 | — | — | US | disclosed |
| EP-0975634-B1 | FUNGICIDAL TRIFLUOROPHENYL-TRIAZOLOPYRIMIDINES | BASF AG (DE) | 2001-07-04 | — | — | EP | disclosed |
| US-6117876-A | Fungicidal trifluorophenyl-triazolopyrimidines | AMERICAN CYANAMID COMPANY (US) | 2000-09-12 | — | — | US | disclosed |
| EP-0975634-A1 | FUNGICIDAL TRIFLUOROPHENYL-TRIAZOLOPYRIMIDINES | AMERICAN CYANAMID COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046607-A1 | FUNGICIDAL TRIFLUOROPHENYL-TRIAZOLOPYRIMIDINES | AMERICAN CYANAMID COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | TUBB3, TUBA1C, TUBB1 | GABBR2 3703/4885GABBR1 3677/4885ADORA3 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.